Comparative Pharmacology
Head-to-head clinical analysis: FML S versus RAXAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FML S versus RAXAR.
FML-S vs RAXAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluorometholone is a synthetic corticosteroid that binds to the glucocorticoid receptor, modulating gene expression to inhibit phospholipase A2 activity, reduce prostaglandin and leukotriene synthesis, and suppress cytokine production. This results in decreased inflammation, edema, and immune cell infiltration. Sulfacetamide is a sulfonamide antibiotic that competitively inhibits dihydropteroate synthase, blocking folate synthesis and bacterial growth.
RAXAR (revumenib) is a selective inhibitor of the menin-KMT2A protein-protein interaction. By binding to menin, it blocks the interaction with KMT2A (MLL1), thereby disrupting the transcription of oncogenic genes such as HOXA9 and MEIS1, leading to differentiation and apoptosis of leukemic cells.
1-2 drops of 0.1% ophthalmic suspension into the conjunctival sac every 4 hours; may increase to every 2 hours in severe inflammation.
Subcutaneous injection: 200 mg once daily, irrespective of timing of meals.
None Documented
None Documented
2.8-3.5 hours; prolonged to 8-12 hours in renal impairment or in neonates
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged in hepatic impairment (up to 25 hours).
Renal (65-75% as unchanged drug and metabolites), biliary/fecal (15-25%)
Primarily hepatic metabolism; renal excretion of unchanged drug <5%; biliary/fecal elimination as metabolites accounts for >90% of total clearance.
Category C
Category C
Ophthalmic Antibiotic/Corticosteroid Combination
Ophthalmic Antibiotic